Harmony Biosciences Holdings Inc HRMY

NAS: HRMY | ISIN: US4131971040   30/04/2025
29,47 USD (+0,10%)
(+0,10%)   30/04/2025

21 augustus 2024 · Harmony Biosciences To Participate In Upcoming Investor Conferences · Persbericht

23 juli 2024 · Harmony Biosciences To Report Second Quarter 2024 Financial Results On August 6, 2024 · Persbericht

25 juni 2024 · HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) · Persbericht

24 juni 2024 · Harmony Biosciences Receives U.s. Food And Drug Administration Approval For Wakix® (Pitolisant) In Pediatric Patients With Narcolepsy · Persbericht

5 juni 2024 · Harmony Biosciences Presents Positive Data For Pitolisant In The Treatment Of Excessive Daytime Sleepiness And Fatigue In Myotonic Dystrophy Type 1 · Persbericht

28 mei 2024 · HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE · Persbericht

30 april 2024 · Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets · Persbericht

16 april 2024 · Harmony Biosciences To Report First Quarter 2024 Financial Results On April 30, 2024 · Persbericht

11 april 2024 · Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist · Persbericht

3 april 2024 · Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) Of Pitolisant In Patients With Prader-Willi Syndrome · Persbericht

26 maart 2024 · Harmony Biosciences To Participate In 23Rd Annual Needham Virtual Healthcare Conference · Persbericht

28 februari 2024 · Harmony Biosciences To Participate In Upcoming Investor Conferences · Persbericht

21 februari 2024 · U.s. Food And Drug Administration Grants Priority Review To Harmony Biosciences' Application For Wakix® (Pitolisant) In Pediatric Narcolepsy · Persbericht

20 februari 2024 · Harmony Biosciences Receives U.s. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-Willi Syndrome · Persbericht

8 februari 2024 · Harmony Biosciences To Report Fourth Quarter And Full Year 2023 Financial Results On February 22, 2024 · Persbericht

8 januari 2024 · Harmony Biosciences Preliminary Unaudited Fourth Quarter And Full Year 2023 Net Product Revenue Increases More Than 30 Percent; Provides 2024 Net Product Revenue Guidance · Persbericht

3 januari 2024 · Harmony Biosciences To Present At The 42Nd Annual J.p. Morgan Healthcare Conference · Persbericht

7 december 2023 · Harmony Biosciences Announces Positive Topline Data From Phase 2 Signal Detection Study Evaluating Pitolisant In Adult Patients With Myotonic Dystrophy Type 1 · Persbericht

5 december 2023 · Harmony Biosciences To Present Results From Behavioral Study In 22Q11.2 Deletion Syndrome At American College Of Neuropsychopharmacology Annual Meeting · Persbericht

8 november 2023 · Harmony Biosciences Appoints Peter Anastasiou To Its Board Of Directors · Persbericht

Mijn selecties